PRG3

Across TCGA pan-cancer cohorts, PRG3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRG3 data layer compared with 10 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRG3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRG3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where PRG3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.508	0.287	.005	23	view →
CCRCC	DFS	Median	All	0.893	0.721	.020	5	view →
UCEC	DFS	Median	II,III,IV	0.867	0.549	.046	4	view →
LUAD	DFS	Quartile	All	0.961	0.911	.026	3	view →
LSCC	DFS	Tertile	All	1.000	0.597	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRG3–PDAC (DFS)

Open the PDAC breakdown →